Good day, and thank you for standing by. Welcome to the InnovAge Q4 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star one one on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star one one again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Ryan Kubota, Director of Investor Relations. Please go ahead. Thank you, operator. Good afternoon, and thank you all for joining the InnovAge 2024 Fiscal Q4 and Fiscal Year-End Earnings Call. With me today is Patrick Blair, President and CEO, and Ben Adams, CFO. Today, after the market closed, we issued a press release containing detailed information on our Q4 and annual results. You may access the release on the Investor Relations section of our company website, innovage.com. For those listening to the rebroadcast of this call, we remind you that the remarks made herein are as of today, Tuesday, September tenth, 2024, and have not been updated subsequent to this call. During our call, we will refer to certain non-GAAP measures. A reconciliation of these measures to the most directly comparable GAAP measures can be found in our earnings press release posted on our website. We will also be making forward-looking statements, including statements related to our full fiscal 2025 year projections, future growth prospects and growth strategy, our clinical and operational value initiatives, Medicare rate increases, census headwinds, the status of current and future regulatory actions, and other expectations. Listeners are cautioned that all of our forward-looking statements involve certain assumptions and are inherently subject to risks and uncertainties that can cause our actual results to differ materially from our current expectations. We advise listeners to review the risk factors discussed in our annual report on Form 10-K for fiscal year 2024 and any subsequent reports filed with the SEC. After the completion of our prepared remarks, we will open the call for questions. I will now turn the call over to our President and CEO, Patrick Blair. Patrick? Thank you, Ryan, and good afternoon, everyone. I want to begin by expressing my continued appreciation to our colleagues, participants, government partners, and the investor community who support InnovAge. Today, we will provide several updates on our financial results for the Q4 and full year fiscal 2024, initial guidance for fiscal year 2025, and progress in our key focus areas. Let me start with our Q4 performance. Today, we reported revenue of approximately $199 million, a sequential improvement of approximately 3.3% compared to the Q3. Center level contribution margin was $36.6 million, which represents an 18.3% margin. As Ben will cover in more detail, we have revised our definition of adjusted EBITDA this year, resulting in Q4 adjusted EBITDA of approximately $5.2 million, which represents a 2.6% margin. We finished the year with a census of approximately 7,020, just shy of the company's high watermark of 7,074 in mid-fiscal 2022. Our Q4 completes a solid year of operating and financial performance. Moving to full year performance, we reported total revenue of approximately $764 million, an increase of approximately 11% compared to fiscal year 2023. Center level contribution margin was approximately $132 million, which represents a 17.3% margin. Year over year, center level contribution margin increased by approximately 260 basis points, from 14.7% to 17.3%, driven by census growth, disciplined medical cost management, and administrative cost controls. Consolidated Adjusted EBITDA was $16.5 million under our revised presentation, which represents a 2.2% margin compared to -$3.4 million in fiscal 2023, an improvement of approximately $20 million. Under the previous presentation, our fiscal 2024 EBITDA would have been $19.8 million, which compares favorably to our full year guidance of $12 million-$18 million. We are proud of the strong year-over-year financial results and the positive momentum as we move out of the rebuilding period of our transformation and into the next phase of responsible growth and margin recapture. To recap a few fiscal 2024 operating performance milestones, we exceeded our employee engagement, participant satisfaction, and quality targets. We acquired two California centers. We executed a joint venture with Orlando Health. We opened two new state-of-the-art centers in Florida. We further strengthened the essential payer capabilities in areas such as Medicaid rate, actuarial soundness, risk score accuracy, provider network optimization, and medical cost management. We increased center utilization by 440 basis points in our established centers. We completed the Epic EMR rollout in all 20 centers, and we sold a non-core senior living facility and reinvested in our core business. We outlined an ambitious agenda last year, and we believe we delivered. I'm proud of our team for their perseverance while keeping high-quality, compliant care as our top priority. We plan to do the same in fiscal 2025. We feel confident that we have created a differentiated and powerful platform from which to grow responsibly and profitably in fiscal 2025, and we believe we are on track to achieve the full potential of the organization in the years to come. Turning now to our fiscal year 2025 guidance. We project a census range of 7,300-7,750 member months of 86,000-89,000, total revenue of $815 million-$865 million, consolidated Adjusted EBITDA of $24-$31 million, and de novo losses of $18-$20 million. We anticipate seeing improvement in our profitability as the year progresses and exiting the year with a higher run rate earnings. Consistent with the targets we provided at our February Investor Day, we expect our Adjusted EBITDA margins to reach 8%-9% over the intermediate term. Ben will take you through a more detailed fiscal 2025 guidance review in a few minutes. Now on to existing center growth. We used fiscal 2024 to test and learn. We launched a new telephonic inside sales team to handle the increased lead volume from our referral partners and digital marketing campaigns. We built new referral partnerships, which have created greater awareness of the PACE program and extended our reach into the communities we serve. We also optimized our digital campaigns, which increased the volume and yield of qualified leads, and we invested in tools and technology to make our enrollment teams more effective and productive. However, as we mentioned on the last couple of quarterly calls, challenges persist with enrollment processing times in some states. Specifically, we have been experiencing state delays completing the level of care assessments required for enrollment in PACE. We continue working closely with our state partners to address these delays and are beginning to see improvement. Despite this headwind, we anticipate healthy overall top-line growth and remain encouraged by robust demand for the PACE model of care. While we remain confident that these challenges will be resolved, the exact timing is not clear, and the uncertainty is reflected in our guidance. Should these challenges abate more quickly than anticipated, we would expect modest upside to our census this year. In our de novo centers, we continue to make progress despite a slower start than we anticipated. Our new centers in Florida are gaining traction as we build awareness of PACE and InnovAge. In Orlando, specifically, we have created a joint venture with Orlando Health, consistent with our strategy to find new avenues for growth by establishing partnerships with leading health system brands in our communities. The partnership is in the early stages, but we're excited by the potential, and we're honored to be working with such an outstanding organization. In our new Crenshaw Center, we're beginning to see our enrollment trend up on a month-over-month basis, and we're largely hitting the mark on our expectations. It's important to note that the full year impact of these new centers will create additional year-over-year operating losses in fiscal 2025 as we work through the maturity curve of each of these de novo centers. On the regulatory front, our focus is on bringing our California audits to conclusion. The San Bernardino state audit commenced in March, and the exit interview is anticipated within the next two months. In Sacramento, we submitted our corrective action plan to the state in March and are still awaiting final feedback. Recall in March, CMS officially closed its portion of the audit. Following resolution of the audits and corrective actions in San Bernardino and Sacramento, we expect to resume discussions with the state regarding the reinstatement of our Downey and Bakersfield expansion plans. Operationally, we remain laser-focused on delivering compliant, high-quality care, with strong medical management and operating discipline at every center. To that end, our fiscal 2024 external provider costs, PMPM, increased by approximately 3% in an inflationary environment where core healthcare cost trends significantly exceeded this level. This provides confidence that our operational and clinical teams are focused on the right levers, which drive high-quality care while reducing unnecessary utilization. While we implemented several new clinical value initiatives last year, we expect to see the full year impact this year, and we'll accelerate actions to drive continuous improvement and new initiatives in fiscal 2025. As we enter year two on the Epic system, we are beginning to experience the benefits in care coordination, documentation, compliance, and risk score accuracy. Further, we have introduced operational value initiatives, or OVIs, to complement our clinical value initiatives. These initiatives are focused on identifying value creation opportunities at the center level and the corporate SG&A level to drive staff productivity, operating efficiency, and improve vendor unit economics from better leveraging people, process, and technology. The foundations for operational excellence are in place across the organization. Now we must execute a little better every day. In closing, we continue to make tangible progress every quarter. We have more top and bottom-line work to do, but we're pleased with our fiscal year 2024 performance and are confident in our fiscal year 2025 guidance. We view fiscal 2025 as an important year to achieving our long-term goals, and you can expect the same execution focus that you've seen from this team for the last two years. Lastly, I want to extend my deepest gratitude to our more than 2,000 employees who embrace our mission every day and enable our participants to have more healthy days. With that, I'll turn it over to Ben. Ben? Thank you, Patrick. Today, I'll provide some highlights from our Q4 and fiscal year-end 2024 financial performance, followed by our fiscal year 2025 guidance. Starting off with fiscal 2024 highlights, I am pleased with our overall performance and our strong finish to the year. The business's total revenue improved each quarter during the past fiscal year, and as Patrick and I have reiterated, we believe we are on the path to normalized margins over the intermediate term. Starting with census, we served approximately 7,020 participants across 20 centers as of June 30, 2024. This represents an increase of 9.6% from 2023, and a 2.8% increase compared to the Q3 of 2024. We reported 80,800 member months in fiscal 2024, a 4.5% increase compared to the prior year. Total revenue increased by 11% to $763.9 million for fiscal year 2024. The increase was primarily driven by an increase in member months, primarily due to the release of sanctions in our Sacramento, California center and at our Colorado centers, and an increase in both Medicaid and Medicare capitation rates. Compared to the Q3, total revenue increased by 3.3% to $199.4 million in the Q4, primarily due to an increase in member months, coupled with retroactive Medicare risk adjustment payments recognized in the Q4. We incurred $403 million of external provider costs during the fiscal year, a 7.6% increase compared to fiscal year 2023. The increase was primarily driven by an increase in member months, coupled with an increase in cost per participant. The cost per participant increase was primarily driven by higher assisted living utilization and unit costs, as well as an increase in costs associated with higher utilization of professional services. These costs were partially offset by a reduction in permanent nursing facility utilization. For the Q4 of fiscal 2024, we incurred $102.7 million of external provider costs, a 2.7% increase compared to the Q3. The sequential increase was primarily driven by an increase in member months, coupled with an increase in inpatient and assisted living facility unit costs. Cost of care, excluding depreciation and amortization, was $228.8 million for fiscal year 2024, a 7.8% increase compared to fiscal year 2023. The increase was primarily due to an increase in cost per participant, coupled with an increase in member months. The increase in cost per participant was driven by an increase in salaries, wages, and benefits associated with increased headcount to support growth and higher wage rates. An increase in contract provider expense in California to support growth, increased fleet expense and contract transportation as a result of higher average daily attendance, an increase in external appointments and higher fuel costs, increased building maintenance and security, an increase in software license fees, and an increase in de novo occupancy and administrative costs, inclusive of the Concerto acquisition in December 2023. This was partially offset by a reduction in costs associated with third-party audit and compliance support. In the Q4, cost of care increased 1.8% to $60.1 million compared to the Q3. The increase was primarily due to an increase in headcount and contract providers in California. Center level contribution margin, which we define as total revenue, less external provider costs and cost of care, excluding depreciation and amortization, which includes all medical and pharmacy costs, was $132.1 million for fiscal year 2024, a 30.4% increase compared to fiscal year 2023. As a percentage of revenue, our center level contribution margin ratio increased approximately 260 basis points to 17.3%, compared to 14.7% in the prior year. For the Q4, center level contribution margin was $36.6 million, compared to $34 million in the Q3. As a percentage of revenue, center level contribution margin increased approximately 70 basis points to 18.3%, compared to 17.6% in the Q3. Sales and marketing expense was $25 million for fiscal year 2024, an increase of $5.3 million compared to fiscal year 2023. The increase was primarily driven by increased marketing spend and an increase in salary, wages, and benefits associated with increased headcount, both of which were associated with the release of sanctions at our Colorado and Sacramento, California centers, and the opening of our new Tampa and Orlando centers in Florida. In the Q4, sales and marketing expense was $6.5 million, a decrease of approximately $600,000 compared to the prior quarter. The decrease was primarily due to lower marketing spend in the quarter as we continued to refine our digital strategy and focus on lead quality. This follows the increased marketing spend in the Q3 for our newly opened Tampa center and recently acquired Crenshaw Center. Corporate, general, and administrative expense decreased to $111.3 million, a $4.3 million decrease compared to fiscal year 2023. The decrease was primarily due to reductions in third-party legal expense, insurance expense, consulting costs associated with improving organizational capabilities, including our transition to Epic, a reduction in contract staffing, and lower recruiting expense. The decrease was partially offset by costs associated with an increase in headcount, bad debt expense, and consulting costs, including SOX compliance, internal audit support, and public relations. Corporate, general, and administrative expense increased to $29.6 million in the Q4, a $2 million increase compared to the Q3. The increase was primarily due to an increase in third-party legal expense, partially offset by a reduction in D&O insurance expense. We reported a net loss of $23.2 million in fiscal 2024, compared to a net loss of $43.6 million in fiscal 2023. On a per-share basis, we reported a net loss of $0.16, compared to $0.30 in fiscal 2023. For the Q4, we reported a net loss of $2.3 million, compared to a net loss of $6.2 million in the Q3. We reported a net loss per share of $0.01 on both a basic and diluted basis, and our weighted average share count was approximately 136 million shares for the quarter on both a basic and fully diluted basis. Effective for fiscal 2024, we revised our calculation of Adjusted EBITDA to reflect the impact of other investment income and to no longer exclude de novo center development costs. We believe this revised presentation more closely reflects our operating core performance as we return to growth. All numbers for prior periods have been recast to conform to this revised presentation. Fiscal year 2024 adjusted EBITDA was $16.5 million, compared to an adjusted EBITDA loss of $3.4 million in fiscal 2023, an approximately $20 million improvement. Our adjusted EBITDA margin was 2.2% for fiscal 2024, compared to an adjusted EBITDA margin loss of 0.5% in the prior fiscal year. We reported adjusted EBITDA of $5.2 million for the Q4, compared to $3 million in the Q3, and our adjusted EBITDA margin was 2.6% for the Q4, compared to 1.5% in the Q3. Under the previous presentation, our fiscal 2024 EBITDA would have been $19.8 million, which compares favorably to our full-year guidance of $12 million to $18 million. De novo losses, which are not included in our Adjusted EBITDA calculation, and which we define as net losses related to pre-opening and startup ramp through the first twenty-four months of de novo operations, were $12 million for fiscal 2024 and primarily related to our centers in Florida and the recently acquired Bakersfield and Crenshaw centers. This compares to $4 million of de novo losses in fiscal 2023. For the Q4, de novo losses were $4.2 million, compared to $4.1 million in the Q3. Turning to our balance sheet, we ended the quarter with $56.9 million in cash and cash equivalents, plus $45.8 million in short-term investments. We had $83.3 million in total debt on the balance sheet, representing debt under our senior secured term loan, plus finance lease obligations and other commitments. For the Q4, we recorded cash flow from operations of $1.9 million, had $3.3 million of capital expenditures, and repurchased approximately 45,000 shares of our common stock for an aggregate of approximately $225,000 under the company's $5 million share repurchase plan. Regarding our fiscal 2025 guidance, which we included in today's press release, based on the information as of today, we expect our ending census for fiscal 2025 to be between 7,300 and 7,750, and member months to be in the range of 86,000 to 89,000. We are projecting total revenue in the range of $815 million-$865 million and adjusted EBITDA in the range of $24 million-$31 million. Finally, we anticipate that de novo losses for fiscal 2025 will be in the $18 million-$20 million range. I will also provide some additional color on a few of the components that comprise our guidance assumptions. Starting with revenue. As a reminder, our Medicaid rates are based on county-specific rates that are adjusted by CMS in January, coupled with prospective risk score adjustments in January and July. For Medicaid, our rates are contractually determined based on cost for PACE or comparable populations in each state. Additionally, in fiscal year 2025, we are updating our reporting methodology by recording bad debt as a contra revenue item rather than as an expense. Our fiscal year 2025 guidance takes this updated reporting methodology into account, and we are expecting a combined mid-single-digit rate increase comprised of the following: A low single-digit Medicare Part C increase, a mid-single-digit Medicare Part D increase, and for Medicaid, a mid-single-digit rate increase, inclusive of an 8.8% increase in Colorado, which includes funding for assisted living and nursing facility unit cost increases effective July 1, 2.5% in Virginia, an estimated low single-digit rate increase in California effective January 1, 2025, and an estimated mid-single-digit rate increase in Pennsylvania effective January 1. We do not anticipate a rate increase in New Mexico at this time. Finally, some thoughts on cost of care, external provider costs, and overall center-level margins. We've made demonstrable progress in the business over the course of fiscal 2024. As we highlighted during our Investor Day back in February, we believe that in the intermediate term, we can achieve Adjusted EBITDA margins in the high single digits. We continue to focus our efforts on maintaining high quality and compliance standards while working diligently to offset annual cost trends with ongoing clinical value initiatives and our new operational value initiatives that Patrick touched on in his remarks. Our fiscal 2025 guidance factors in the strong foundation we've laid for ourselves in fiscal 2024, the initiatives we are implementing to offset annual cost trends, and the temporary census headwinds that Patrick highlighted, driven by state processing delays, which we believe create a compelling and achievable margin growth story towards our target of high single-digit Adjusted EBITDA margins over the intermediate term. We continue to make significant investments in the business, including updating our financial systems to Oracle, while maintaining a disciplined approach to costs and being ever mindful of providing high-quality service and compliance in each of our centers. In closing, we believe we are continuing to make improvements to the business every quarter. We remain focused on day-to-day operational execution and continuing the earnings momentum we laid the groundwork for in fiscal 2024. Operator, that concludes our prepared remarks. Please open the call for questions. Thank you, and at this time, we will conduct a question-and-answer session. As a reminder, to ask a question, you will need to press star one one on your telephone and wait for your name to be announced. To withdraw your question, please press star one one again. Please stand by. We'll compile the Q&A roster. One moment for our first question. Our first question comes from the line of Jason Cassorla from Citi. Your line is open. Great, thanks. Good afternoon. It sounds like you're expecting a more linear progression on EBITDA this year or for fiscal 2025, but maybe can you just walk us through those puts and takes? It sounds like that's driven more on the, like, the fixed cost leverage with census continuing to build throughout the year, and then separately, are there any one-time items inside that $16.5 million of EBITDA you did for fiscal 2024 that we just need to contemplate as we think about growth for the 2025 guidance range? Or is that $16.5 million a pretty clean kind of baseline number for jump off in your view? Sure. Hey, it's Ben Adams. Sort of breaking it apart, I guess I would think about the guidance for next year is very much of kind of a building off of the growth trends that we've seen this year. If you think about our census numbers and our member months, you know, we've actually now had almost an entire year post-sanctions of, you know, pretty good enrollment trends. So we've actually got a pretty good handle on what's going on. We've spoken a little bit in the past about some of the state processing delays that we've had, and so we've factored those into the trends that we've seen in the business going forward. And so what you see there is very much a building off of the trends that we've seen this year. Obviously, we've got a couple of new de novo centers that are rolling into those numbers to a lesser degree, but it's very much of a trend-based analysis. I think if you look on the revenue side, I think we talked about some of the guidance we had in there about Medicare Part C, Part D rates, and also what's going on in state Medicaid rates. I think, you know, you think about those generally as kind of like mid-single digit rates. So the delta between that and the revenue growth is really built off of volume for the most part, and then when we're thinking about EBITDA, obviously, you know, we go through sort of a center-by-center buildup. There's some assumptions in there that Patrick may want to comment on here around OVIs and CVIs. You know, we had a lot of success last year with our clinical value initiatives, so we've got a whole new set of them rolling in this year, as well as the new ones on the operational side, which we call OVIs. So what we see in the guidance is basically an expectation about how those are gonna mature over the course of the year. And then the last thing I would say in terms of de novo losses, obviously, you know, we've got, you know, basically four new centers that are in various states of immaturity, and we've got a pretty good handle on what the run rate of those expenses are gonna be like over the next year. And so those are basically just built off of those assumptions at for those de novo centers. It's a pretty straightforward build in terms of the analysis going forward. I think we feel, you know, pretty good about the range that we put out there. You got it. Okay, great. Thanks, and maybe just a little bit more color. I know you kind of put out that 3.5% or so margin target, midpoint of guide. I guess, can you just give us a little bit more on how you're thinking about that target relative to the 8%-9% intermediate that you gave at your Investor Day? I guess, just would you expect a little bit more of a J-curve type of ramp in the margin trajectory of the business into 2026 and beyond? Just kind of like, you know, thinking about how that, you're positioning, kind of, your margin expectation for this year against kind of the growth and the expectation for 8%-9% over time. Thanks. Yeah, yeah, sure. So when we think about the margin progression over time, when we went through our Investor Day, I guess it was in February. I think we talked about getting to sort of an 8%-9% margin range over the intermediate term, which we kind of defined as two years to four years, and so I would just look at it and basically say, you know, we stand by that ramp. You know, where we are today is very much sort of a stop along the journey. We think it'll probably progress pretty linearly over that period of time. And as we sort of look at where we are right now and how the business is trending and what we think is gonna happen next year, it feels like we're, you know, tracking, you know, right according to expectations for that target. So again, I think that two to four years from the Investor Day is probably the right timeframe to look at. So we're, whatever we are, six or eight months beyond that Investor Day, so. Yeah, I would just say that, you know, we're just providing fiscal year 2025 guidance today, but as the year develops, we'll have, you know, increasing visibility into fiscal year 2026 and the slope of the margin recapture. And we'll be sure to, you know, keep everybody informed of how that progresses. Great, thanks. So if I can squeak in one more, can you just give us a sense, if I'm understanding right, just 2024 revenue with the bad debt change? I guess, just kind of if you do the back of the envelope math, it would suggest, like, aggregate PMPMs are only up slightly for 2025, but you kind of applied a mid-single digit rate increase. Just curious, like, what if acuity has a dampening effect on that as you're bringing on new members, just any color in and around that, as we think about modeling for this year? Yeah, let me give you some general guidance here. The simple answer is, basically, this doesn't affect profitability. This is strictly moving the geography of an expense on the income statement. So instead of being, excuse me, an expense item down below, it basically is gonna be contra revenue in the future. If you were to look at that expense, you know, related to 2024, you know, think about a number that's probably kind of like the $6-$7 million range. So if you were trying to go back and adjust 2024, to sort of put it on an apples-to-apples basis, so you could look at the growth rates, you know, think of like a $6-$7 million number, as an adjustment to 2024, and then the guidance we gave you for 2025, and then off of that, you can kind of compute an apples-to-apples growth rate. And when you think about what's going on there, there's nothing really related to the acuity of the population or anything else going on, other than it's just being booked as contra revenue now, because in consultation with our auditors, because of the characteristics of the bad debt expense, they just view it as under 606 as a contra revenue item now. Okay, awesome. Thank you for the color. Thank you. One moment for our next question. Our next question comes from the line of John Stansel from J.P. Morgan Securities. Your line is open. Great. Thanks for taking the question. Just a quick one on cadence of enrollment. You know, obviously, with some of the enrollments trending up in, say, Crenshaw, how are you thinking about the balance of membership adds across the year? And then conversely, the cadence of de novo losses for that 18-20 million headwind to Adjusted EBITDA? You want to go? Well, I'll start with the, you know, the enrollment, unless you add from there. You know, in terms of how we expect the enrollment to come in, you know, I don't see a lot of difference between fiscal year 2024 and fiscal year 2025, you know, we still expect the preponderance of our enrollment to come associated with California and Colorado in particular. Our three new centers in Tampa, Orlando, and Crenshaw are still ramping up. We are pleased with the traction we're starting to see in all those markets. You know, admittedly, Florida is taking a little longer to get to the ramp that we're seeing now, and we've learned a lot about, you know, de novos. These are our first de novos in several years, and we're starting to see that progress that we expected the last couple of months, and we're excited about our partnership with Orlando Health, you know, in particular. And so I feel like, you know, the enrollment's going to track pretty much the way it did in fiscal year 2024. Ben? Yeah, and I would just say, your question about de novo losses, I would just think them as kind of being spread generally evenly over the course of the year. You know, these facilities are up and running. You know, they change slightly quarter to quarter, but in terms of modeling purposes, just think of them as kind of a linear progression over the course of the year. Great. And then I know you called out, I think, a mid-single digit increase in Medicare Part D. Is there anything you'd highlight as we enter calendar 2025 around IRA impacts to how you're thinking about that side of the business? No, I don't think so. I think that, you know, the guidance sort of it is what it is on that. And that's, you know, probably how I would think about it from a modeling perspective. Okay, thank you. Thank you. And once again, that's star one one for questions, star one one. One moment for our next question. Our next question will come from the line of Jared Haase from William Blair. Your line is open. Yeah, good evening, thanks for taking the questions. Maybe just a quick follow-up. I just wanted to clarify the sort of state delays or the headwinds that are still impacting the census growth. Just to clarify, is that all still kind of related to Medicaid redeterminations largely? I think that was the case last quarter, but just wanted to check on that. And it seems like, you know, as we get closer to the end of that wind down process, that should clear up in relatively short order. Is that something you would agree with? And then also, are those delays still kind of limited to certain markets, or are you seeing that kind of broad-based across the different states that you operate in? Yeah, the first question, I think you're right. I think we're sort of seeing the last of the impacts of redetermination. I think the challenges we're experiencing, as I said in my opening remarks, are more related to sort of the throughput and the long level of care assessments that the states perform as a final stage to enrollment, and we've seen some delays. You know, I wouldn't say that it's widespread, but it is impacting us in some of our larger states, where we see most of our gross enrollment volume, you know, in a month. And so we've made great progress, I think, since the last quarter, but there's still vestiges that we've got to work through. And I think that our, you know, our guidance appropriately reflects what we know today. And, should we make some progress there, you know, we're going to hopefully see some upside to our gross enrollment for the year. Okay, that's great, and then maybe I'll take a step back and ask a bigger picture question. You know, we've seen some signs of health systems kind of increasingly getting interested in launching PACE programs, and, you know, I'm thinking specifically about the Kaiser venture in California as one example. How are you thinking about that dynamic? I guess, both in terms of maybe a source of competition in the market as health systems kind of look to launch de novos, or potentially as an unlock to, you know, continue to be that partner of choice for joint ventures, you know, just obviously given the scale and the clinical investments and the expertise that you have in terms of this market. You know, I'd say, first and foremost, we're very encouraged by the interest in PACE and, you know, the move by Kaiser to enter PACE is, you know, from our perspective, very welcome. You know, the notion of competition in PACE is primarily relevant in California, where they allow more than one PACE program to operate in a particular territory, and that's relevant to Kaiser's first entry. But as you know, in most other states, the territories are, in essence, exclusive. I don't think that we view it necessarily as a significant source of competition, but rather, you know, a very reputable organization seeing a business opportunity with you know a large business across the U.S., and that should have a very positive impact on sort of building PACE awareness. We look forward to working closely with them and all the other PACE programs to build awareness for PACE. It really does, I think, validate the model. At the same time, it takes a lot of time for you know PACE programs from the point of expressing interest to you know operating a viable program. So, you know, we view ourselves as, in many ways, you know, an early market leader and are continuing to see a significant opportunity. And, you know, more competition is only gonna build awareness for a wonderful program. Got it. That's super helpful. Thanks for all the color. Thank you. And with that, this concludes the question and answer session. Thank you for your participation in today's conference. This does conclude the program. You may now disconnect. Everyone, have a great day.